BOSTON, January 10, 2025: Morgan Lewis represented Ankyra Therapeutics in the company’s expanded collaboration with Johnson & Johnson to advance the clinical development of a drug conjugate that is currently in Phase 1 clinical trials for solid tumors.
Under the new agreement, Ankyra will broaden its plan to test ANK-101 in clinical trials to assess its safety and potential benefits for patients with non-small cell lung cancer (NSCLC), the most common form of lung cancer.
Ankyra is a Cambridge, Massachusetts–based biotechnology company offering a technology platform that expands the therapeutic window of therapeutic drugs.
Partners Stephen Altieri, Andrew Haupt, and Ben Stein and associate Natalie Nicelli advised Ankyra.
